Effects of carbamazepine on the hypothalamic-pituitary-thyroid axis.

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
D BonguU M Kabadi

Abstract

To evaluate the effects of treatment with carbamazepine on the hypothalamic-pituitary-thyroid axis and thyroid hormone concentrations in patients with epilepsy. We undertook a prospective study in seven subjects in whom the diagnosis of epilepsy had been established and a regimen of carbamazepine (200 mg three times a day) was initiated. All participants underwent 24-hour 123 I thyroid uptake studies, as well as assessment of the basal thyrotropin concentration and the thyrotropin response to intravenous administration of thyrotropin-releasing hormone. In addition, thyroxine (T(4)), free T(4) index, triiodothyronine (T(3)), free T(3) index, reverse T(3), and T(3) resin uptake were determined before initiation of carbamazepine treatment and again after 3 to 4 months of carbamazepine therapy. Serum T(4), T(3), and free T(4) index decreased significantly (P<0.05) after therapy with carbamazepine, whereas no significant alterations were noted in T(3) resin uptake, free T(3) index, and reverse T(3) concentrations. A significant increase occurred in basal serum thyrotropin level (P<0.05). Moreover, the peak thyrotropin concentration, the absolute change from the basal thyrotropin level, and an integrated thyrotropin response expresse...Continue Reading

References

May 1, 1977·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·A Conti, H Studer
Dec 1, 1978·Scandinavian Journal of Clinical and Laboratory Investigation·K RootweltS I Johannessen
Mar 1, 1976·Scandinavian Journal of Clinical and Laboratory Investigation·K Liewendahl, H Majuri
Nov 1, 1979·Metabolism: Clinical and Experimental·R R CavalieriK Cruse
Jun 17, 1978·British Medical Journal·P P YeoD C Evered
Jun 1, 1990·Archives of Neurology·J I IsojärviV V Myllylä
Feb 1, 1990·Endocrine Reviews·R Ekins
Nov 1, 1989·Archives of Neurology·J I IsojärviV V Myllylä
Apr 1, 1988·Journal of the American Geriatrics Society·U M Kabadi, P M Rosman
Nov 1, 1988·The Journal of Clinical Endocrinology and Metabolism·M I SurksL E Shapiro
Oct 1, 1988·The Journal of Clinical Endocrinology and Metabolism·C F LimJ R Stockigt
Feb 1, 1985·The Journal of Endocrinology·J A FranklynM C Sheppard
Nov 1, 1985·Metabolism: Clinical and Experimental·T IkedaH Mashiba
Oct 1, 1974·The Journal of Clinical Endocrinology and Metabolism·J M HansenK Siersbaek-Nielsen
Feb 1, 1968·The Journal of Clinical Endocrinology and Metabolism·W Chin, G C Schussler
May 1, 1970·The Journal of Clinical Investigation·L E BravermanK Sterling
Jun 1, 1970·The Journal of Clinical Investigation·P R LarsenR E Goldsmith
Jun 1, 1971·The Journal of Clinical Investigation·C S PittmanV H Read
Jan 1, 1984·Endocrine Reviews·P J Smith, M I Surks
Jan 1, 1984·European Journal of Clinical Pharmacology·J M ConnellM J Brodie
Sep 1, 1984·British Journal of Clinical Pharmacology·E PeruccaA Richens
Jan 1, 1984·European Journal of Clinical Pharmacology·J A FranklynD B Ramsden
Sep 1, 1983·Annals of Internal Medicine·J L BlackshearD D Stuart
Sep 1, 1980·The Journal of Clinical Endocrinology and Metabolism·E M KapteinJ T Nicoloff
Feb 1, 1981·Acta Neurologica Scandinavica·R E StrandjordS I Johannessen
Oct 1, 1981·European Journal of Clinical Investigation·E E OhnhausH Studer
Dec 1, 1994·Clinical Endocrinology·G Van den BergheP Lauwers
Jun 1, 1993·Acta Paediatrica Japonica; Overseas Edition·A YükselA Cenani
Jun 1, 1993·Journal of Neurology, Neurosurgery, and Psychiatry·J I IsojärviV V Myllylä
Mar 1, 1961·The Journal of Clinical Endocrinology and Metabolism·J H OPPENHEIMERJ W JAILER

❮ Previous
Next ❯

Citations

Jul 20, 2005·Treatments in Endocrinology·Nick Clarke, Udaya M Kabadi
Oct 6, 2015·Expert Review of Clinical Pharmacology·Sherifa Ahmed Hamed
Jun 10, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Burç C PoyrazIbrahim Balcioğlu
Apr 13, 2007·European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society·Achilleas AttilakosEustathia Katsarou

❮ Previous
Next ❯

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
U M Kabadi, M M Kabadi
Immunology and Allergy Clinics of North America
Jeffrey S Rumbyrt, Alan L Schocket
© 2022 Meta ULC. All rights reserved